A Phase I, Open-label Trial to Investigate Metabolism, Pharmacokinetics (Following a Mass Balance Design) and Absolute Bioavailability of BI 690517 (C-14) After Oral and Intravenous Administration in Healthy Male Subjects

Boehringer Ingelheim1 site in 1 country14 target enrollmentSeptember 19, 2022

ConditionsHealthy

InterventionsBI 690517 (C-14)BI 690517

Overview

Phase: Phase 1
Intervention: BI 690517 (C-14)
Conditions: Healthy
Sponsor: Boehringer Ingelheim
Enrollment: 14
Locations: 1
Primary Endpoint: Part A: Fraction of [14C] radioactivity excreted into urine given as percentage of the administered dose in the time interval from 0 to last quantifiable time point (fe urine,0-tz )
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.

Registry

clinicaltrials.gov

Start Date

September 19, 2022

End Date

November 17, 2022

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

Boehringer Ingelheim

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests.
•Age of 18 to 55 years (inclusive).
•Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive).
•Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.

Exclusion Criteria

•Subjects will not be allowed to participate, if any of the following general criteria apply:
•Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator.
•Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 45 to 90 mmHg, or pulse rate outside the range of 40 to 100 beats per minute (bpm).
•Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
•Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
•Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
•Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair).
•Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders.
•History of relevant orthostatic hypotension (including but not limited to a reduction in systolic BP of ≥20 mm Hg or in diastolic BP of ≥10 mm Hg within 3 minutes of standing during screening measurement associated with clinical symptoms), fainting spells, or blackouts.
•Further exclusion criteria apply.

Arms & Interventions

Part A: BI 690517 (C-14)

Intervention: BI 690517 (C-14)

Part B: BI 690517 fasted (test treatment, T) / BI 690517 (C-14) (reference treatment, R)

Intervention: BI 690517 (C-14)

Part B: BI 690517 fasted (test treatment, T) / BI 690517 (C-14) (reference treatment, R)

Intervention: BI 690517

Outcomes

Primary Outcomes

Part A: Fraction of [14C] radioactivity excreted into urine given as percentage of the administered dose in the time interval from 0 to last quantifiable time point (fe urine,0-tz )

Time Frame: Up to 22 days.

Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after intravenous administration (AUC0-∞)

Time Frame: Up to 3 days.

Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after oral administration (AUC0-∞)

Time Frame: Up to 3 days.

Part A: Fraction of [14C] radioactivity excreted into feces given as percentage of the administered dose in the time interval from 0 to last quantifiable time point (fe feces, 0-tz)

Time Frame: Up to 22 days.

Secondary Outcomes

Part B: Maximum measured concentration of the analyte in plasma (Cmax)(Up to 3 days.)
Part A: Maximum measured concentration of the analyte in plasma (Cmax)(Up to 8 days.)
Part A: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz)(Up to 8 days.)
Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz)(Up to 3 days.)